Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24


Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model.

Grossman I, Kolitz S, Komlosh A, Zeskind B, Weinstein V, Laifenfeld D, Gilbert A, Bar-Ilan O, Fowler KD, Hasson T, Konya A, Wells-Knecht K, Loupe P, Melamed-Gal S, Molotsky T, Krispin R, Papir G, Sahly Y, Hayden MR.

Ann N Y Acad Sci. 2017 Nov;1407(1):75-89. doi: 10.1111/nyas.13547.


Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images.

Guo S, Lai C, Wu C, Cen G; Alzheimer's Disease Neuroimaging Initiative.

Front Aging Neurosci. 2017 May 18;9:146. doi: 10.3389/fnagi.2017.00146. eCollection 2017. Erratum in: Front Aging Neurosci. 2017 Sep 05;9:293.


A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.

Ross CJ, Towfic F, Shankar J, Laifenfeld D, Thoma M, Davis M, Weiner B, Kusko R, Zeskind B, Knappertz V, Grossman I, Hayden MR.

Genome Med. 2017 May 31;9(1):50. doi: 10.1186/s13073-017-0436-y.


Drug repurposing from the perspective of pharmaceutical companies.

Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E, Papapetropoulos S, Grossman I, Laifenfeld D.

Br J Pharmacol. 2018 Jan;175(2):168-180. doi: 10.1111/bph.13798. Epub 2017 May 18. Review.


Letter to the Editor response: Nygaard et al.

Towfic F, Kusko R, Zeskind B.

Biostatistics. 2017 Apr 1;18(2):197-199. doi: 10.1093/biostatistics/kxw031.


Pridopidine activates neuroprotective pathways impaired in Huntington Disease.

Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, -Wagner AM, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, Zeskind B, Grossman I, Hayden MR.

Hum Mol Genet. 2016 Sep 15;25(18):3975-3987. doi: 10.1093/hmg/ddw238. Epub 2016 Jul 27.


Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.

Grossman I, Knappertz V, Laifenfeld D, Ross C, Zeskind B, Kolitz S, Ladkani D, Hayardeny L, Loupe P, Laufer R, Hayden M.

Prog Neurobiol. 2017 May;152:114-130. doi: 10.1016/j.pneurobio.2016.02.001. Epub 2016 Mar 4. Review.


Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.

Hasson T, Kolitz S, Towfic F, Laifenfeld D, Bakshi S, Beriozkin O, Shacham-Abramson M, Timan B, Fowler KD, Birnberg T, Konya A, Komlosh A, Ladkani D, Hayden MR, Zeskind B, Grossman I.

J Neuroimmunol. 2016 Jan 15;290:84-95. doi: 10.1016/j.jneuroim.2015.11.020. Epub 2015 Nov 24.


Rates of Adverse Events and Multiple Sclerosis Relapses Before and After Introduction of a Purported Generic Glatiramer Acetate in mexico: Results from a Large Patient Support Program in Mexico.

Ramirez D, Flores J, Verdi D, Gandhi S, Grossman I, Zeskind B, Grinspan A.

Value Health. 2015 Nov;18(7):A877. doi: 10.1016/j.jval.2015.09.050. Epub 2015 Oct 20. No abstract available.


Leveraging existing data sets to generate new insights into Alzheimer's disease biology in specific patient subsets.

Fowler KD, Funt JM, Artyomov MN, Zeskind B, Kolitz SE, Towfic F.

Sci Rep. 2015 Sep 23;5:14324. doi: 10.1038/srep14324.


Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.

Kolitz S, Hasson T, Towfic F, Funt JM, Bakshi S, Fowler KD, Laifenfeld D, Grinspan A, Artyomov MN, Birnberg T, Schwartz R, Komlosh A, Hayardeny L, Ladkani D, Hayden MR, Zeskind B, Grossman I.

Sci Rep. 2015 May 22;5:10191. doi: 10.1038/srep10191.


Use of genetic technologies to compare medicines.

Kolitz SE, Towfic F, Grossman I, Hayden MR, Zeskind B.

Clin Genet. 2014 Nov;86(5):441-6. doi: 10.1111/cge.12462. Epub 2014 Sep 8. Review.


Comparing the biological impact of glatiramer acetate with the biological impact of a generic.

Towfic F, Funt JM, Fowler KD, Bakshi S, Blaugrund E, Artyomov MN, Hayden MR, Ladkani D, Schwartz R, Zeskind B.

PLoS One. 2014 Jan 8;9(1):e83757. doi: 10.1371/journal.pone.0083757. eCollection 2014.


Lebrikizumab treatment in adults with asthma.

Zeskind B.

N Engl J Med. 2011 Dec 22;365(25):2432; author reply 2433-4. doi: 10.1056/NEJMc1112234#SA1. No abstract available.


Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume.

Carmichael O, Xie J, Fletcher E, Singh B, DeCarli C; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2012 Jun;33(6):1124.e31-41. doi: 10.1016/j.neurobiolaging.2011.08.016. Epub 2011 Dec 14.


IL-6 and ovarian cancer--letter.

Locasale JW, Zeskind B.

Clin Cancer Res. 2011 Dec 15;17(24):7837; author reply 7838. doi: 10.1158/1078-0432.CCR-11-2170. Epub 2011 Dec 6. No abstract available.


Maximizing the efficacy of angiogenesis inhibitors.

Locasale JW, Zeskind BJ.

J Clin Oncol. 2012 Jan 20;30(3):337-8; author reply 338-9. doi: 10.1200/JCO.2011.38.5435. Epub 2011 Dec 5. No abstract available.


Detecting global and local hippocampal shape changes in Alzheimer's disease using statistical shape models.

Shen KK, Fripp J, Mériaudeau F, Chételat G, Salvado O, Bourgeat P; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2012 Feb 1;59(3):2155-66. doi: 10.1016/j.neuroimage.2011.10.014. Epub 2011 Oct 14.


Individual subject classification for Alzheimer's disease based on incremental learning using a spatial frequency representation of cortical thickness data.

Cho Y, Seong JK, Jeong Y, Shin SY; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2012 Feb 1;59(3):2217-30. doi: 10.1016/j.neuroimage.2011.09.085. Epub 2011 Oct 8.


BEaST: brain extraction based on nonlocal segmentation technique.

Eskildsen SF, Coupé P, Fonov V, Manjón JV, Leung KK, Guizard N, Wassef SN, Østergaard LR, Collins DL; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2012 Feb 1;59(3):2362-73. doi: 10.1016/j.neuroimage.2011.09.012. Epub 2011 Sep 16.

Supplemental Content

Loading ...
Support Center